NCT01953432View on ClinicalTrials.gov

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 1, 2014

Primary Completion Date

September 1, 2017

Study Completion Date

October 1, 2017

Conditions
Cocaine Dependence
Interventions
DRUG

Doxazosin

Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.

DRUG

Placebo

Matched placebo daily dosing

Trial Locations (1)

77030

Michael E. DeBakey VA Medical Center, Houston, TX, Houston

All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

lead

VA Office of Research and Development

FED

NCT01953432 - Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse | Biotech Hunter | Biotech Hunter